| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $62M | ||
| $60M |
Buys | $82,199,970 | 6 | 14 |
Sells | $77,662,640 | 37 | 86 |
| RA CAPITAL MANAGEMENT, L.P. | director | 2 | $47.5M | 0 | $0 | $47.5M |
| AKKARAJU SRINIVAS | director | 2 | $23.1M | 0 | $0 | $23.1M |
| Samsara BioCapital GP, LLC | 10 percent owner | 1 | $8.1M | 0 | $0 | $8.1M |
| Slingsby Brian Taylor | 1 | $3.5M | 1 | $43.35M | $-39.85M | |
| Karydas Daphne | director | 0 | $0 | 1 | $689,797 | $-689,797 |
| Gold Alexander M | director | 0 | $0 | 3 | $1.58M | $-1.58M |
| Levy Adam Scott | CFO and Secretary | 0 | $0 | 8 | $7.52M | $-7.52M |
| Congleton Jon | Chief Executive Officer | 0 | $0 | 6 | $11.26M | $-11.26M |
| Rodman David Malcom | Chief Medical Officer | 0 | $0 | 18 | $13.27M | $-13.27M |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Over the last 12 months, insiders at Mineralys Therapeutics, Inc. have bought $82.2M and sold $77.66M worth of Mineralys Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Mineralys Therapeutics, Inc. have bought $57.4M and sold $30.33M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. (director) — $47.5M. AKKARAJU SRINIVAS (director) — $23.1M. Samsara BioCapital GP, LLC (10 percent owner) — $8.1M.
The last purchase of 588,235 shares for transaction amount of $15M was made by AKKARAJU SRINIVAS (director) on 2025‑09‑04.
| 2026-02-13 | Sale | Rodman David Malcom | Chief Medical Officer | 10,514 0.0158% | $27.48 | $288,957 | +0.43% | |
| 2026-02-12 | Sale | Rodman David Malcom | Chief Medical Officer | 6,349 0.01% | $28.99 | $184,077 | -0.81% | |
| 2026-02-09 | Sale | Rodman David Malcom | Chief Medical Officer | 2,171 0.0031% | $30.21 | $65,586 | -8.19% | |
| 2026-01-20 | Sale | Rodman David Malcom | Chief Medical Officer | 416 0.0006% | $32.10 | $13,354 | -1.44% | |
| 2026-01-14 | Sale | Rodman David Malcom | Chief Medical Officer | 11,367 0.0167% | $32.61 | $370,645 | -5.80% | |
| 2026-01-13 | Sale | Rodman David Malcom | Chief Medical Officer | 7,709 0.0116% | $32.75 | $252,470 | -4.08% | |
| 2026-01-12 | Sale | Congleton Jon | Chief Executive Officer | 16,236 0.0242% | $32.62 | $529,640 | -3.85% | |
| 2026-01-12 | Sale | Rodman David Malcom | Chief Medical Officer | 6,348 0.0094% | $32.32 | $205,143 | -3.85% | |
| 2026-01-12 | Sale | Levy Adam Scott | CFO and Secretary | 10,758 0.0158% | $32.14 | $345,723 | -3.85% | |
| 2026-01-09 | Sale | Rodman David Malcom | Chief Medical Officer | 2,170 0.0033% | $33.27 | $72,196 | -4.91% | |
| 2026-01-05 | Sale | Rodman David Malcom | Chief Medical Officer | 192,715 0.2855% | $35.02 | $6.75M | -10.52% | |
| 2026-01-02 | Sale | Rodman David Malcom | Chief Medical Officer | 70,037 0.1044% | $35.87 | $2.51M | -10.59% | |
| 2025-11-20 | Sale | Slingsby Brian Taylor | 1M 1.5617% | $43.35 | $43.35M | -14.83% | ||
| 2025-11-13 | Sale | Karydas Daphne | director | 15,000 0.0235% | $45.99 | $689,797 | -19.02% | |
| 2025-11-13 | Sale | Gold Alexander M | director | 12,742 0.0202% | $46.50 | $592,503 | -19.02% | |
| 2025-11-12 | Sale | Gold Alexander M | director | 6,933 0.0128% | $46.72 | $323,886 | -23.90% | |
| 2025-11-11 | Sale | Congleton Jon | Chief Executive Officer | 200,000 0.3606% | $45.44 | $9.09M | -23.52% | |
| 2025-11-11 | Sale | Levy Adam Scott | CFO and Secretary | 119,524 0.2128% | $44.88 | $5.36M | -23.52% | |
| 2025-11-11 | Sale | Gold Alexander M | director | 15,000 0.0262% | $43.98 | $659,706 | -23.52% | |
| 2025-10-15 | Sale | Rodman David Malcom | Chief Medical Officer | 10,369 0.0155% | $43.01 | $445,982 | -14.63% |
| Slingsby Brian Taylor | 7903838 11.9221% | $218.15M | 1 | 2 | ||
| Samsara BioCapital GP, LLC | 10 percent owner | 5674916 8.56% | $156.63M | 2 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | director | 5456521 8.2306% | $150.6M | 3 | 0 | |
| Congleton Jon | Chief Executive Officer | 639151 0.9641% | $17.64M | 4 | 15 | +24.98% |
| AKKARAJU SRINIVAS | director | 588235 0.8873% | $16.24M | 2 | 0 | |
| Rodman David Malcom | Chief Medical Officer | 44089 0.0665% | $1.22M | 0 | 24 | |
| Levy Adam Scott | CFO and Secretary | 8638 0.013% | $238,408.80 | 0 | 12 | |
| Karydas Daphne | director | 0 0% | $0 | 0 | 1 | |
| Gold Alexander M | director | 0 0% | $0 | 0 | 3 | |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 3218106 4.8542% | $88.82M | 1 | 0 |
$831,902,292 | 108 | 9.34% | $1.74B | |
$100,473,344 | 83 | 9.53% | $1.56B | |
$54,590,806 | 65 | 21.84% | $1.93B | |
$1,103,317,478 | 60 | 36.54% | $1.67B | |
$47,419,530 | 58 | 17.20% | $1.86B | |
$1,376,668 | 53 | 18.46% | $1.82B | |
$571,084,134 | 44 | 4.33% | $1.9B | |
$82,281,805 | 29 | -1.52% | $1.69B | |
$62,927,079 | 29 | 14.02% | $2B | |
$25,045,414 | 23 | -3.79% | $1.97B | |
$8,195,601 | 23 | -12.08% | $2.03B | |
$12,094,896 | 19 | 20.07% | $1.88B | |
$154,554,190 | 14 | 29.60% | $1.64B | |
$144,557,026 | 13 | 0.49% | $1.78B | |
$94,976,497 | 10 | -10.72% | $1.82B | |
$2,859,892 | 10 | 29.21% | $1.78B | |
$25,073,947 | 7 | -5.99% | $2.07B | |
$4,623,072 | 7 | 11.07% | $1.98B | |
Mineralys Therapeutics, Inc. (MLYS) | $7,605,533 | 5 | 17.10% | $1.83B |
| Increased Positions | 131 | +84.52% | 24M | +37.63% |
| Decreased Positions | 71 | -45.81% | 8M | -12.81% |
| New Positions | 52 | New | 9M | New |
| Sold Out Positions | 11 | Sold Out | 450,234 | Sold Out |
| Total Postitions | 215 | +38.71% | 81M | +24.82% |
| Catalys Pacific, Llc | $317,956.00 | 11.27% | 8.9M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $261,531.00 | 9.27% | 7.32M | +1M | +19.14% | 2025-09-30 |
| Samsara Biocapital, Llc | $223,657.00 | 7.93% | 6.26M | +588,235 | +10.37% | 2025-09-30 |
| Blackrock, Inc. | $131,113.00 | 4.65% | 3.67M | +573,854 | +18.52% | 2025-09-30 |
| Vanguard Group Inc | $107,808.00 | 3.82% | 3.02M | +692,550 | +29.77% | 2025-09-30 |
| Caligan Partners Lp | $99,011.00 | 3.51% | 2.77M | +755,302 | +37.44% | 2025-09-30 |
| Capital International Investors | $85,468.00 | 3.03% | 2.39M | -505,624 | -17.44% | 2025-09-30 |
| Suvretta Capital Management, Llc | $76,138.00 | 2.7% | 2.13M | +387,641 | +22.22% | 2025-09-30 |
| Sr One Capital Management, Lp | $75,489.00 | 2.68% | 2.11M | -1M | -32.42% | 2025-09-30 |
| Fmr Llc | $73,965.00 | 2.62% | 2.07M | +2M | +579.35% | 2025-09-30 |